% | $
Quotes you view appear here for quick access.

YM BioSciences, Inc. Ordinary S Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • C78596998785 C78596998785 Dec 17, 2010 7:17 PM Flag


    I asked earlier in the week if anyone's broker was making a market in the stock... The large institutional investers buy from the offering and resell to their clients... in this case it looks like the shares went to other institutional buyers... these shares do not show as trade activity...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • And I see Roth has a buy rating for YMI.

      This is a summary from Roth..

      Joseph Pantginis, Ph.D., Senior Research Analyst
      t: 646-358-1907, e:

      Joseph Pantginis, Ph.D. joined Roth Capital Partners in 2009. Prior to joining Roth Dr. Pantginis was a senior biotech analyst at Merriman Curhan Ford. Dr. Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JBHanauer & Co., First Albany Corporation, Commerce Capital Markets and Ladenburg Thalmann & Co., Inc. Prior to his tenure on Wall Street, Dr. Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Dr. Pantginis received an M.B.A. in Finance from Pace University; a Ph.D. in Molecular Genetics and an M.S. from Albert Einstein College of Medicine; and a B.S. from Fordham University.